On March 5, the Centers for Disease Control and Prevention a published a National Vital Statistics Report on the drugs most ...

Study of 600,000 US military veterans shows that those who took anti-obesity medications were less likely to develop some complications of substance-use disorders.

A new study finds that popular GLP-1 drugs used to treat diabetes and obesity show new promise in fighting multiple substance use disorders.

Novo's drug, CagriSema, didn't achieve its key goal of demonstrating non-inferiority on weight loss when compared to Eli Lilly's rival drug tirzepatide. The stock plummeted on Monday, hitting its ...

Tirzepatide (Zepbound, Mounjaro) is a dual-agonist GLP-1 medication. It works like a GLP-1 agonist, but also targets a hormone called glucose-dependent insulinotropic polypeptide (GIP) to “help break ...

Abstract: Machine learning has been successfully applied to drug combination prediction in recent years. However, in some situations, the class imbalance problem still shows highly negative impacts on ...

Pfizer Inc. is drawing on lessons learned years ago from rolling out Viagra as it maps out the launch of its first obesity medicine. The parallels between weight loss and erectile dysfunction — two ...

CARDIFF, UK / ACCESS Newswire / February 19, 2026 / Biodexa Pharmaceuticals PLC (NASDAQ:BDRX), a clinical-stage biopharmaceutical company developing a pipeline of innovative products for the treatment ...

PADUCAH — A McCracken County Grand Jury indicted 10 individuals for drug trafficking offenses in early February. According to the Paducah Police Department, drug detectives received information in ...

Cambridge, UK, 16 February 2026: Harness Therapeutics (‘Harness’), a biotechnology company unlocking previously undruggable targets to transform the treatment of neurodegenerative diseases, today ...

Trainer Eddie Clouston, who was third in earnings and second in victories at the 2025 Mountaineer Park meet, has been suspended six months and fined $5,000 by that track's stewards stemming from a ...

Novo Nordisk CEO Mike Doustdar has a plan to steer the company through what’s been described as a “show me” year. The Danish drugmaker kicked off 2026 with its explosive obesity pill launch, but ...